Your browser version may not work well with NCBI's Web applications. More information here...
1: Arthritis Res Ther. 2003;5 Suppl 4:S7-11. Epub 2003 Oct 2.Click here to read Links

Targeting B cells for the treatment of rheumatoid arthritis.

Oligino TJ, Dalrymple SA.

Roche Pharmaceuticals, Palo Alto, California, USA. tom.oligino@roche.com

The role of B cells in rheumatoid arthritis (RA) has been debated for decades. However, recent clinical trial data indicating that depletion of B cells in RA patients is of therapeutic benefit has validated the importance of this cell type in the pathogenesis of the disease. Elucidation of the molecular basis of B cell development and activation has allowed the identification of a number of possible therapeutic targets that are appealing for drug development. This review discusses briefly a number of these molecules and the rationale for targeting them for the treatment of RA.

PMID: 15180891 [PubMed - indexed for MEDLINE]

Patient Drug Information